Efficacy and safety of chemotherapy regimens in elderly patients with newly diagnosed transplant-ineligible multiple myeloma under different health status
CSTR:
Author:
Affiliation:

(Department of Hematology, Hengshui People′ s Hospital, Hengshui 053000, Hebei Province, China)

Clc Number:

Fund Project:

This work was supported by Hengshui2023AnnualScience and TechnologyPlan(First Batch)Project(2023014O37Z).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective To evaluate the efficacy and safety of chemotherapy regimens in elderly patients with newly diagnosed transplant-ineligible multiple myeloma (MM) under different health status. Methods A retrospective analysis was conducted of the clinical data of 150 elderly patients with newly diagnosed transplant-ineligible MM in Hengshui People′ s Hospital from June 2021 to June 2023. The patients′ baseline health status was assessed using a frailty scoring method based on comprehensive geriatric assessment. According to the assessment results, the patients were divided into a frail group (n=54), a generally healthy group (n=50) and a healthy group (n=46). The chemotherapy effect and chemotherapy-related adverse reactions were compared among the three groups. Data analysis was performed by SPSS 27.0. Kaplan-Meier curves were plotted to analyze the 1-year cumulative survival rate of the three groups. Results The proportions of patients achieving efficacy complete response (CR) or better, very good partial response (VGPR) or better, and partial response (PR) or better in the frail group were all lower than those in the healthy group, and the proportion of patients achieving PR or better was lower than that in generally healthy group (P<0.05). In the healthy group, the proportion of patients achieving VGPR or better with daratumumab/bortezomib/melphalan/prednisone (D-VMP) was higher than that with doublet or triplet regiments (P<0.05). The incidence of liver function abnormalities, ≥ grade 3 hematological adverse reactions, and thrombotic events in the frail group was higher than that in both the healthy group and the generally healthy group, and the incidence of peripheral neuropathy was higher than that in the healthy group (P<0.05). In the healthy group, the incidence rate of peripheral neuropathy with D-VMP treatment was higher than that with doublet regimens. In the generally healthy group, the incidence rate of ≥ grade 3 hematological adverse reactions, thrombotic events, infections, and peripheral neuropathy with D-VMP treatment was higher than that with doublet regimens. In the frail group, the incidence of liver function abnormalities, ≥ grade 3 hematological adverse reactions, thrombotic events, and infections with D-VMP treatment was higher than that with doublet regimens, and all differences were statistically significant (P<0.05). The 1-year cumulative survival rate was 74.80% in the healthy group, 58.3% in the generally healthy group, and 52.10% in the frail group. There was a statistically significant difference in the cumulative survival rate among the three groups (log-rank χ2=8.661, P=0.013). Conclusion The baseline health status based on frailty score is a critical factor affecting the efficacy and prognosis of chemotherapy in elderly patients with newly diagnosed transplant-ineligible MM. D-VMP treatment yields the best efficacy in healthy elderly MM patients, while its efficacy is not significant in generally healthy and frail patients. Notably, the incidence of adverse reactions during D-VMP treatment is higher, necessitating enhanced clinical monitoring of adverse reactions and potential adjustments or modifications in the treatment regimens when necessary.

    Reference
    Related
    Cited by
Get Citation
Related Videos

Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:February 17,2025
  • Revised:
  • Adopted:
  • Online: February 03,2026
  • Published:
Article QR Code